Ian Boulton is Managing Director of TropMed Pharma Consulting (TMPC), a company specialising in working with public and private sector organisations working in the field of diseases of poverty (including malaria, TB, and dengue). Prior to setting up TMPC in 2008, he worked for nearly 35 years in the pharmaceutical industry across a wide range of disciplines. Twenty years of this were spent in Asia where he first experienced the impact of diseases of poverty and the fragility of the healthcare systems in many of those countries. Between 2000-2008, he was one of the leaders of GlaxoSmithKline’s Diseases of the Developing World Initiative, where he was responsible for the development and management of GSK’s strategy in malaria, TB, and other neglected diseases. During this time he was involved in several public-private partnerships to develop new, affordable, and practical drugs to treat diseases in low- and middle-income countries.
For four years, Ian was a Board Member of the Roll Back Malaria Partnership (RBM), representing the private sector. Since leaving the industry and setting up TMPC, he has advised and worked on projects with WHO, RBM, Global Fund, Gates Foundation, London & Liverpool Schools, Medicines for Malaria Venture, TB Alliance, UNITAID, and other public and private sector organisations.
Ian was previously a Trustee of Malaria Consortium between 2009 and 2015, and has been a member of the Finance, Audit, & Risk Committee since 2015.